On January 28, SAI hosted a global webinar on China Pharmaceutical Innovation & Invention Index (PIII), bringing together industry professionals to explore the China’s pharmaceutical innovation and deep dive into a growing number of local enterprises which are advancing innovative R&D and globalization efforts, thus actively participating in reshaping the global pharmaceutical landscape.
The webinar attracted over 100 registrations, with approximately 60 participants attending at peak, reflecting strong interest in objective, data-driven perspectives on innovation and R&D performance in the China biopharma market.
The session was presented by Jacqueline Poot, President of Strategic Consulting & Analytics at IDEA Pharma (a division of SAI), and Ryan Li, Head of Market Access & RWE at SAI Asia. Together, they introduced the key results of China PIII 2025, the first ever new data-driven benchmark designed to objectively assess how effectively Chinese biopharma companies convert their pipelines into meaningful innovations and value and lifts the veil on how R&D innovation in China is being driven in a way that’s not been seen before.
A highlight of the webinar was the expert panel discussion session with Prof. William Jia, Co-Founder and Chief Scientific Officer of Virogin Biotech. Drawing on his experience in innovation-driven R&D, Prof. Jia shared practical insights into translating scientific pipelines into meaningful outcomes in an increasingly competitive environment.
In an industry where every decision can impact a life, understanding true innovation is not just helpful. It’s essential… Please come to talk with us on the Global and China PIII findings and whitepapers.
Please download the full report via link:
https://www.ideapharma.com/pii
You can also see the recording here on our YouTube channel:
https://www.youtube.com/watch?v=KH57MlOLTm0